RxDoctor Payments Data

Heather Dailey

Family · Jackson, OHNPI 1356773196

Payments from drug & device makers

$1,855in general payments, 2019–2025

Across 103 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$470
  • Novo Nordisk$377
  • AstraZeneca$323
  • Bayer$188
  • Lilly USA, LLC$170
  • Boehringer Ingelheim$128
  • plus $200 from 5 others

What the payments were for

  • Food & beverage$1,855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,855 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$2,707
Medicare patients
76
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide20$25,526
EliquisApixaban22$15,805
OzempicSemaglutide18$15,244
FarxigaDapagliflozin Propanediol11$14,049
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,485
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,979
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,437
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,263
SymbicortBudesonide/Formoterol Fumarate11$2,865
Albuterol Sulfate HfaAlbuterol Sulfate78$2,312
Levothyroxine Sodium152$1,940
Potassium Chloride74$1,662
Gabapentin126$1,419
Metoprolol Succinate98$1,352
Atorvastatin Calcium174$1,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$323$25,89436 claims
Lilly USA, LLCMounjaro$170$25,52620 claims
Novo NordiskOzempic$377$15,24418 claims
GSKTrelegy Ellipta, Anoro Ellipta$18$13,92226 claims
AbbVieSynthroid$470$56212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.

Other family in Jackson

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →